Diagnostic value of circulating microRNAs for lung cancer: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 5, 2013, Pages 359-366

  Shen, Yongchun ^a   Wang, Tao ^a   Yang, Ting ^a   Hu, Qianjing ^a   Wan, Chun ^a   Chen, Lei ^a   Wen, Fuqiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LUNG CANCER; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

HUMANS; LUNG NEOPLASMS; MICRORNAS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84876914224     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0370     Document Type: Article

References (40)

1. Aberle DR, Berg CD, Black WC, et al. (2011) The National Lung Screening Trial: overview and study design. Radiology 258:243-253.
2. Bach PB, Jett JR, Pastorino U, et al. (2007) Computed tomography screening and lung cancer outcomes. JAMA 297:953-961.
3. Bianchi F, Nicassio F, Marzi M, et al. (2011) A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3:495-503.
4. Bishop JA, Benjamin H, Cholakh H, et al. (2010) Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16:610-619.
5. Boeri M, Verri C, Conte D, et al. (2011) MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108:3713-3718.
6. Chen W, Zhang S, Zou X (2010) Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi 13:488-493.
7. Chen X, Ba Y, Ma L, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997-1006.
8. Chen X, Hu Z, Wang W, et al. (2012) Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130:1620-1628.
9. Cho WC (2011) Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer. Expert Rev Mol Diagn 11:763-766.
10. Deeks JJ, Altman DG (2004) Diagnostic tests 4: likelihood ratios. BMJ 329:168-169.
11. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882-93.
12. Devillé WL, Buntinx F, Bouter LM, et al. (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9.
13. Foss KM, Sima C, Ugolini D, et al. (2011) miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 6:482-488.
14. Glas AS, Lijmer JG, Prins MH, et al. (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129-1135.
15. Heegaard NH, Schetter AJ, Welsh JA, et al. (2012) Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 130:1378-1386.
16. Heneghan HM, Miller N, Kerin MJ (2010) Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 28:e573-4; author reply e575-e576.
17. Hennessey PT, Sanford T, Choudhary A, et al. (2012) Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 7:e32307.
18. Hu Z, Chen X, Zhao Y, et al. (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721-1726.
19. Jemal A, Siegel R, Xu J, et al. (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
20. Jeong HC, Kim EK, Lee JH, et al. (2011) Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. Mol Med Report 4:383-387.
21. Jones CM, Athanasiou T (2005) Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 79:16-20.
22. Leeflang MM, Deeks JJ, Gatsonis C, et al. (2008) Systematic reviews of diagnostic test accuracy. Ann Intern Med 149: 889-897.
23. Leidinger P, Keller A, Borries A, et al. (2011) Specific peripheral miRNA profiles for distinguishing lung cancer from COPD. Lung Cancer 74:41-47.
24. Li YZ, Li W, Ouyang QC, et al. (2011) Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncol Lett 2:991-994.
25. Lin PY, Yang PC (2011) Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med 3:436-437.
26. Lu X, Yang X, Zhang Z, et al. (2010) Meta-analysis of serum tumor markers in lung cancer. Zhongguo Fei Ai Za Zhi 13:1136-1140.
27. Ma YX, Tian ZN, Zhang W (2012) Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 138:2045-2050.
28. Markou A, Tsaroucha EG, Kaklamanis L, et al. (2008) Prognostic value of mature microRNA-21 and microRNA-205 over-expression in non-small cell lung cancer by quantitative realtime RT-PCR. Clin Chem 54:1696-1704.
29. Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006-1012.
30. Pritchard CC, Cheng HH, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13:358-369.
31. Qi J, Mu D (2012) MicroRNAs and lung cancers: from patho-genesis to clinical implications. Front Med 6:134-155.
32. Shen J, Liu Z, Todd NW, et al. (2011a) Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11:374.
33. Shen J, Todd NW, Zhang H, et al. (2011b) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 91:579-587.
34. Stiles BM, Altorki NK (2011) Screening for lung cancer: challenges for the thoracic surgeon. Surg Oncol Clin N Am 20: 619-635.
35. Walter SD (2002) Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21:1237-1256.
36. Wang B, Zhang Q (2012) The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol 138:1659-1666.
37. Wei J, Gao W, Zhu CJ, et al. (2011) Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30:407-414.
38. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605-613.
39. Whiting PF, Weswood ME, Rutjes AW, et al. (2006) Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 6:9.
40. Zheng D, Haddadin S, Wang Y, et al. (2011) Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 4:575-586.